Key clinical point: Anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAb) are an effective treatment option for vestibular migraine (VM), with a large proportion of patients showing simultaneous reduction in migraine days, vertigo days, and Migraine Disability Assessment (MIDAS) score.
Major finding: At 12 months after CGRP mAb treatment, the mean monthly dizziness/vestibular symptom days (mean difference [MD] 9.5 days), headache frequency (MD 13.8 days), and MIDAS score (MD 36.1) were significantly reduced in the overall cohort (P < .001) and 78% of patients showed ≥50% reduction in all 3 parameters.
Study details: Findings are from a prospective observational cohort study including 50 patients with chronic migraine who met the criteria for VM and were treated with fremanezumab (n = 25), galcanezumab (n = 18), or erenumab (n = 7).
Disclosures: This study did not receive any funding. CV Russo, F Sacca, and R De Simone declared receiving personal compensation, public speaking honoraria, or consulting fees from various sources.
Source: Russo CV et al. Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study. Cephalalgia. 2023;43(4):3331024231161809 (Mar 22). Doi: 10.1177/03331024231161809